In a world with an increasing number of resistant and difficult-to-treat microbes, Pharma Holdings has set off to develop new drugs that are rapid acting and with a low propensity towards resistance development. Our new generation cationic peptide is the result of world-class research in the field of lytic peptides. Further, our compound LTX-109 is derived from a naturally occurring peptide which, together with the low drive towards resistance development, ensures a sustainable way of fighting off infections currently threatening the global health.